1. Pink Sheet
  2. >>Market Access
  3. >>PBMs

This Year, PBM-Directed Fury May Once Again Signify Nothing

 
• By Leslie Small

Anti-PBM sentiment continues to rise, but industry observers still question whether the reforms being discussed will be effective.

2025 Pink Sheet Perspectives
Industry observers questioned whether the PBM status quo will change, even if reform legislation is enacted. (Shutterstock)
Key Takeaways
  • Industry observers predicted that the risk of regulatory changes for PBMs will increase in 2025, but some were not sure reforms would be effective.
  • Employers, PBMs largest clients, also are not racing to upset the status quo, which may mean the sector may not be impacted much.
  • PBMs’ heavy investment in biosimilar manufacturing and distribution also is likely to continue.

Federal legislators failed to act on the rising tide of anti-PBM sentiment in 2024, but health policy experts predict that the risk of regulatory intervention will ramp up this year even with Republicans, who traditionally

But some industry observers appear skeptical federal reforms will be very effective, especially because major PBMs likely will continue seeing demand

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from PBMs

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

PBMs No Longer Profit From Rebates But Plans Benefit; Should Sponsors Push More For Reform?

 
• By Cathy Kelly

Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.

PBMs Must Prepare For Revival Of Drug Price Transparency Requirements

 
• By Jill Drachenberg

Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.

More from Pink Sheet Perspectives